Drug Discovery World

APRIL 26, 2024

In addition to encoding the target antigens, mRNA vaccines also provide adjuvant properties that amplify the immune response. A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK. in the combination arm and 62.2%

Clinical Trials 130

Clinical Trials Vaccine Trials Immune Response 130

The Pharma Data

JANUARY 25, 2021

Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company. And safety outcomes were similar in the REGN-COV2 dose groups and the placebo group.

Immune Response 52

Immune Response Treatment Clinical Trials Hospitals 52

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

Drug Discovery World

OCTOBER 21, 2022

While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US 1 ), outcomes are still poor in certain cancers that do not respond to standard therapies. Advances in understanding treatment resistant cancer cells (part 1).

Therapies 130

Therapies Small Molecule Immune Response Engineering 130

The Pharma Data

MARCH 8, 2022

However, the antiviral immune receptor RIG-I can be stimulated, which improves protection against lethal SARS-CoV-2 infections. While the development of vaccines was accomplished in a remarkably short timeframe, the identification of direct antiviral treatments has progressed comparatively slowly. Researchers led by Prof.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

Drug Discovery World

APRIL 20, 2023

There is a clear opportunity to repurpose some of these candidates for preventative/ prophylactic treatment for post-Covid-19 cognitive impairment. These may provide an opportunity for treatment for post-Covid-19 cognitive impairment. New therapeutics of course depend on an understanding of biological mechanisms.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

OCTOBER 23, 2020

A solidarity clinical trial “is one of the largest international randomized trials for Covid-19 treatments, enrolling almost 12,000 patients in 500 hospital sites in over 30 countries”, according to the World Health Organization (WHO), which launched the trail with a number of partners. Overall, in-hospital mortality was 12.9

Trials 52

Trials Immune Response Hospitals Clinical Trials 52

The Pharma Data

APRIL 8, 2022

Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. ” The results are published today in Nature Communications. .

Virus 52

Virus Immune Response Disease Clinical Trials 52

The Pharma Data

SEPTEMBER 14, 2020

A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. Prof Martin Landray from the University of Oxford, who is co-leading the Recovery Trial, said: “This is the first type of treatment that’s targeted for this specific virus. He said: “We need to understand not only if these treatments work.

Trials 52

Trials Immune Response Virus Vaccine 52

NIH Director's Blog: Drug Development

JUNE 30, 2020

But there is a catch: 99 percent of the study’s participants didn’t make enough neutralizing antibodies to mount an ideal immune response. In early April, Nussenzweig’s team began analyzing samples from volunteer survivors who visited The Rockefeller Hospital to donate plasma, which contains the antibodies.

Immune Response 52

Immune Response Virus Vaccine Research 52

Drug Discovery World

APRIL 14, 2023

Melissa M Hudson, MD – Joseph H Burchenal Award for Outstanding Achievement in Clinical Cancer Research Hudson is a faculty member, Director of the Cancer Survivorship Division, Associate Director, Population Sciences, and The Charles E Williams Endowed Chair of Oncology-Cancer Survivorship at St Jude Children’s Research Hospital.

Clinical Trials 130

Clinical Trials Research Science Clinical Research 130

The Pharma Data

DECEMBER 9, 2020

In the new study, researchers found that among COVID patients at their safety-net hospital, neurological complications ran the gamut. Safety-net hospitals are obligated, by mandate or mission, to treat people regardless of their ability to pay. The patient improved after treatment with anti-inflammatory corticosteroids.

Hospitals 52

Hospitals Doctors Immune Response Nurses 52

The Pharma Data

JANUARY 3, 2021

Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-tolerated. This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses. NEW YORK and LONDON, Jan. NEW YORK and LONDON, Jan.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

hospitals are stretched to the limit trying to help people battling serious cases of COVID-19. Yet the quest to save more lives from COVID-19 isn’t even close to being finished, and researchers continue to work intensively to develop new and better treatments. ACTIV-3 : This Phase 3 trial is enrolling hospitalized adults with COVID-19.

Clinical Trials 52

Clinical Trials Hospitals Vaccine Trials 52

The Pharma Data

APRIL 22, 2023

When infused back into a mouse model of MS, the backpack-laden monocytes were able to affect MS-specific immune responses, and partially reverse hind limb paralysis and improve motor functions. The results are published in the Proceedings of the National Academy of Sciences (PNAS).

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

The Pharma Data

OCTOBER 26, 2020

FDA Approval: Last week the FDA approved Veklury (remdesivir) for the treatment of COVID-19 requiring hospitalization in adults and pediatric patients (12 years of age and older). Only a fraction of intravenous antibody treatments will make their way to the lungs of COVID-19 patients, which is where the infection is primarily located.

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52

Broad Institute

DECEMBER 6, 2023

Using single-cell RNA sequencing to analyze gene expression in individual cells, the researchers have found how 86 major cytokines affect 17 immune cell types in mice. NH: This is the first single-cell resolution dictionary of each major immune cell type responding to each major cytokine in vivo at an unprecedented scale.

Immune Response 138

Immune Response RNA Medical Schools Disease 138

NIH Director's Blog: Drug Development

FEBRUARY 1, 2022

Though more study is needed, the researchers say the decoy therapy could potentially be delivered directly to the lungs through an inhaler and used alone or in combination with other COVID-19 treatments. While the protein worked against both versions of the virus, infection with the more aggressive Gamma variant required earlier treatment.

Virus 52

Virus Engineering Clinical Trials Immune Response 52

The Pharma Data

MARCH 23, 2022

“When the COVID-19 pandemic started, our multidisciplinary research teams switched our investigations of other viruses and bacteria to focus on a potential treatment for what was then a challenging new virus for us,” says Children’s Center microbiologist Lori Jones-Brando, Ph.D., µM) and remdesivir (for example, 0.5-3.2

Virus 52

Virus Immune Response Research Treatment 52

The Pharma Data

NOVEMBER 18, 2020

.” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

NOVEMBER 12, 2020

José Baselga, Executive Vice President, Oncology R&D, said: “Since the beginning of the year, AstraZeneca has been committed to doing everything we can to respond to COVID-19, including investigating existing medicines as potential treatments. CALAVI US). NCT identifier: NCT04380688. Available online. Accessed October 2020.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

The Pharma Data

OCTOBER 16, 2020

COVID-19 Antibody Treatment Study Paused. Immune Responses Long-Lasting After Serious COVID-19. 14, 2020 — Black and Mixed/Other ethnicity are independently associated with greater hospital admission risk due to COVID-19 but are not associated with in-hospital mortality risk, according to a U.K.

Hospitals 52

Hospitals Immune Response Vaccine Trials 52

The Pharma Data

JANUARY 11, 2021

Bin Cao, from the National Center for Respiratory Medicine at the China-Japan Friendship Hospital and Capital Medical University, both in Beijing. And he’s seen similar issues among patients at his hospital. ” The Wuhan study also tried to track survivors’ longer-term immunity against COVID-19. .”

Hospitals 52

Hospitals Virus Vaccine Immune Response 52

Agency IQ

DECEMBER 1, 2023

That guidance, first issued in May 2020 , was released at a time when there were no FDA-approved drugs to treat Covid-19, and the standard-of-care for treatment relied on clinical management of symptoms and supportive care (e.g., supplemental oxygen, mechanical ventilation).

FDA 40

FDA Clinical Trials Vaccine Trials 40

The Pharma Data

JUNE 17, 2022

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now authorized in the U.S.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

OCTOBER 6, 2021

Fluzone High-Dose is the only influenza vaccine that has demonstrated reductions in influenza-related complications such as hospitalizations due to cardiovascular events and pneumonia, over 10 consecutive seasons in more than 34 million people aged 65 and older 1 , 2 , 3. Full results of the study will be published later this year.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

Broad Institute

AUGUST 7, 2023

Now, a team of MIT, Massachusetts General Hospital (MGH), Broad Institute of MIT and Harvard, and Harvard Medical School (HMS) researchers has discovered how STING activates those two pathways. Food and Drug Administration has not approved any STING agonist thus far, although multiple clinical trials are currently underway.

Regulations 91

Regulations Engineering Clinical Trials DNA 91

Broad Institute

OCTOBER 4, 2023

This is an unprecedented opportunity to evaluate how immune responses work,” said Robert Manguso , who is co-senior author on the study, an associate member at the Broad, and an assistant professor at the Massachusetts General Hospital Center for Cancer Research and Harvard Medical School.

Small Molecule 128

Small Molecule Clinical Trials Engineering Medical Schools 128

The Pharma Data

FEBRUARY 23, 2022

. * In the VAT08 Phase 3 primary series trial, two doses of the Sanofi-GSK vaccine in seronegative populations demonstrated: * 100% efficacy against severe COVID-19 disease and hospitalizations * 75% efficacy against moderate or severe COVID-19 disease * 57.9% Favorable safety profile following both primary series and booster vaccinations.

Vaccine 52

Vaccine Virus Trials Immune Response 52

The Pharma Data

NOVEMBER 19, 2020

The study data came from a prospective study of participants at Rutgers and affiliated hospitals during the early phase of the pandemic. The study evaluated 546 healthcare works with direct patient exposure at two hospitals in New Jersey and 283 non-healthcare workers that did not have direct patient contact. Source link.

Research 52

Research Nurses Disease Immune Response 52

The Pharma Data

FEBRUARY 18, 2022

“For clinicians treating patients with this serious, chronic disease, results from the True North extension study provide an understanding of long-term therapeutic outcomes and help to identify an appropriate treatment approach for their patients with ulcerative colitis,” said Silvio Danese, M.D., About Ulcerative Colitis.

Clinical Trials 40

Clinical Trials Immune Response Treatment Disease 40

The Pharma Data

NOVEMBER 1, 2020

In view of the importance and urgency, scientific teams at the Harvard Medical School, Santa Casa de Misericórdia de Santos Hospital (Jabaquara, Santos, Brazil) and at Tiziana are closely collaborating to facilitate initiation of this study in expedited time frames. NEW YORK and LONDON, Nov. Dr Howard Weiner, who is the Robert L.

Clinical Trials 52

Clinical Trials Trials Medical Schools Hospitals 52

The Pharma Data

JANUARY 11, 2021

I-SPY COVID-19 is assessing multiple drugs for critical COVID-19 hospitalized or ICU patients. Dalcetrapib is a potential anti-viral treatment that binds to the catalytic site of 3CLMpro of SARS-CoV-2 in vitro. DalCor Pharmaceuticals initiated the Phase II dal-COVID trial of dalcetrapib for COVID-19.

Vaccine 52

Vaccine Clinical Trials Immune Response Virus 52

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The lead Principal Investigator for the INNOVATE trial is Dr. Pablo Tebas , Professor of Medicine at the Hospital of the University of Pennsylvania.

DNA 40

DNA Vaccine Immune Response Clinical Trials 40

The Pharma Data

OCTOBER 28, 2020

REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits). Clinical results in the overall population (n=799): On the key clinical endpoint, treatment with REGN-COV2 reduced COVID-19 related medical visits by 57% through day 29 (2.8%

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

NOVEMBER 10, 2020

We believe the scientific rationale for oral treatment with Foralumab is logical to facilitate topical action at the inflamed sites in the gastrointestinal tract. Additionally, oral capsules provide the convenience of home use, and increase patient compliance by eliminating the need for infusions in a clinic or hospital setting.

Clinical Trials 40

Clinical Trials Science Disease Trials 40